Holen Sie sich die Stockscreener-App
1.79
5.92%
0.10
Handel nachbörslich:
1.79
Schlusskurs vom Vortag:
$1.69
Offen:
$1.7
24-Stunden-Volumen:
168.66K
Relative Volume:
0.11
Marktkapitalisierung:
$140.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.28%
1M Leistung:
-36.52%
6M Leistung:
+39.84%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.695
$1.80
1-Wochen-Bereich:
$1.67
$1.9877
52-Wochen-Spanne:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Firmenname
Citius Oncology Inc
Sektor
Telefon
(908) 967-6677
Adresse
11 COMMERCE DRIVE, CRANFORD
Vergleichen Sie CTOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.79 | 132.45M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-27 | Eingeleitet | Maxim Group | Buy |
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology Inc. stock chart pattern explained2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
Identifying reversal signals in Citius Oncology Inc.Earnings Trend Report & Real-Time Market Sentiment Alerts - Newser
Citius Oncology Beats Fiscal Q3 EPS - AOL.com
Citius Oncology Beats Q3 EPS Estimates with $0 Revenue - AInvest
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology (CTOR) $9M Offering; Cash Runway Through Sept 2025 | TENKU SEC FilingForm 10-Q - Stock Titan
Citius Secures $21.5M Funding as Cancer Drug LYMPHIR Nears Q4 2025 Commercial Launch - Stock Titan
Risk adjusted return profile for Citius Oncology Inc. analyzedPrice Forecast Based on AI Analysis - Newser
Citius Oncology Announces Pricing of $9.0 Million Public Offering - ADVFN Brasil
Smart tools for monitoring Citius Oncology Inc.’s price actionHigh Yield Signals with Entry Timing - Newser
Citius Oncology Inc. stock trend outlook and recovery pathStrategy Chart for Real-Time Trade Flow - Newser
Chart overlay techniques for tracking Citius Oncology Inc.Free Capital Protection Trading Strategies - Newser
Is Now a Good Time to Reenter Citius Oncology Inc.Watchlist for Low Risk High Return Stocks Updated - beatles.ru
Citius Oncology IncAnticipates Commercial Launch of Lymphir in 2025 - 富途牛牛
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
What analysts say about Citius Oncology Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What institutional investors are buying Citius Oncology Inc. stockInvest smarter with expert stock recommendations - Jammu Links News
What is the risk reward ratio of investing in Citius Oncology Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
How volatile is Citius Oncology Inc. stock compared to the marketGet professional advice for portfolio optimization - Jammu Links News
Does Citius Oncology Inc. stock perform well during market downturnsUnlock real-time stock alerts for quick profits - Jammu Links News
How strong is Citius Oncology Inc. company’s balance sheetSkyrocketing returns - Jammu Links News
What are the latest earnings results for Citius Oncology Inc.Free Stock Market Trend Analysis - Jammu Links News
Why is Citius Oncology Inc. stock attracting strong analyst attentionAchieve breakthrough investment performance - Jammu Links News
What is Citius Oncology Inc. company’s growth strategyBuild a portfolio for long-term financial success - Jammu Links News
Should I hold or sell Citius Oncology Inc. stock in 2025Capitalize on market trends early - Jammu Links News
What drives Citius Oncology Inc. stock priceGet timely market insights for better trades - Jammu Links News
What are analysts’ price targets for Citius Oncology Inc. in the next 12 monthsFree Daily Trading Room Entry - Jammu Links News
How does Citius Oncology Inc. compare to its industry peersBreakthrough stock performance - Jammu Links News
How does Citius Oncology Inc. generate profit in a changing economyPost Market Target Finder To Watch Now - Jammu Links News
What makes Citius Oncology Inc. stock attractive to long term investorsPortfolio Diversification Stock Ideas From Experts - metal.it
Published on: 2025-07-29 19:38:23 - metal.it
Trendline Breach Raises Concern for Citius Oncology Inc. InvestorsFundamental + Technical Hybrid Stock Tips Shared - metal.it
Relative strength of Citius Oncology Inc. in sector analysisFundamental Analysis for Value Stock Selection - Newser
Finanzdaten der Citius Oncology Inc-Aktie (CTOR)
Es liegen keine Finanzdaten für Citius Oncology Inc (CTOR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):